Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib + GP in Advanced Biliary Tract Cancer
NCT05742750Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in biliary tract cancer (BTC), sponsored by Sun Yat-sen University. Primary endpoints: Incidence of dose-limiting toxicity at 22 days, Recommended phase 2 dose of apatinib at 12 weeks and 1 more. Started Apr 2023; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05742750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742750.